BIOMAT Database Logo BIOMAT Database Logo

Cost-effective antimicrobial therapy. 1986

S L Barriere

UI MeSH Term Description Entries
D010607 Pharmacy Service, Hospital Hospital department responsible for the receiving, storing, and distribution of pharmaceutical supplies. Clinical Pharmacy Service,Hospital Pharmacy Service,Pharmacy Service, Clinical,Hospital Pharmaceutic Service,Hospital Pharmaceutical Service,Hospital Pharmacy Services,Pharmaceutic Service, Hospital,Pharmaceutical Service, Hospital,Service, Clinical Pharmacy,Service, Hospital Pharmaceutic,Service, Hospital Pharmaceutical,Service, Hospital Pharmacy,Clinical Pharmacy Services,Hospital Pharmaceutic Services,Hospital Pharmaceutical Services,Pharmaceutic Services, Hospital,Pharmaceutical Services, Hospital,Pharmacy Services, Clinical,Pharmacy Services, Hospital,Services, Clinical Pharmacy,Services, Hospital Pharmaceutic,Services, Hospital Pharmaceutical,Services, Hospital Pharmacy
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents

Related Publications

S L Barriere
Community-acquired pneumonia. Cost-effective antimicrobial therapy.
January 1996, Postgraduate medicine,
S L Barriere
Cost-effective choice of antimicrobial therapy for serious infections.
January 1986, Journal of general internal medicine,
S L Barriere
Antimicrobial stewardship programs - cost-minimizing or cost-effective?
February 2015, Expert opinion on pharmacotherapy,
S L Barriere
Cost-effective antimicrobial therapy: an approach for physicians and community hospitals.
March 1986, Journal of the South Carolina Medical Association (1975),
S L Barriere
Outpatient parenteral antimicrobial therapy for infective endocarditis: a cost-effective strategy.
July 2014, Medecine et maladies infectieuses,
S L Barriere
A cost-effective antimicrobial susceptibility testing system.
April 1998, American clinical laboratory,
S L Barriere
Cost-effective drug therapy.
January 1993, Healthcare executive,
S L Barriere
Cost-effective oxygen therapy.
September 1980, Annals of internal medicine,
S L Barriere
Cost effects of restricting cost-effective therapy.
July 1985, Medical care,
S L Barriere
Antimicrobial therapy. Cost-benefit considerations.
October 1989, Drugs,
Copied contents to your clipboard!